KorvaJoin the waitlist
Money

Windward Bio Raises $175 Million for Asthma Drug Designed for Two Doses a Year

The Swiss biotech priced shares at $17, with $50 million from Sanofi, to fund testing of WIN378.

AI image
realtech.media · Start-ups — news | RealTech Media

Windward Bio, a Swiss biotechnology company, set the terms for a $175 million stock market debut on November 13 to fund work on two immune drugs, including an asthma drug in late stage testing.

The debut was an initial public offering, a first sale of shares to public investors. The money will support continued testing of the lead asthma drug.

The company offered 10.3 million shares priced at $17 each. Sanofi added $50 million.

The lead drug, WIN378 for asthma, is in Phase 2/3 testing, a stage that combines midstage and larger late stage studies in patients.

The company designed WIN378 to be given just two times a year. That schedule is a design goal, not an approved dose, and the ongoing trial has not yet shown whether it will work as planned.

The next measure to watch is the readout from the Phase 2/3 trial, which will shape what the company does next.

Questions people ask

What does it mean to price a $175 million IPO?

A priced offering means the company has set the final share price and share count for its market debut. Here, offering 10.3 million shares at $17 raised about $175 million before fees. That cash goes to the company to pay for research and trials.

What happens in a Phase 2/3 asthma trial?

Phase 2/3 means the drug has moved past early safety tests and is being studied in larger groups of patients. Researchers track both benefit and side effects. Companies usually need positive results before they can seek regulatory approval.

More in Money